Opexa starts phase 2b MS study; cites 90% relapse reduction in earlier trial

By Elaine Rigoli

Tampa, Fla., Sept. 18 - Opexa Therapeutics, Inc. started a phase 2b study with Tovaxin for the treatment of multiple sclerosis and expects that the first patients will be enrolled early in the fourth quarter of this year.

Opexa, a cell therapies company based in The Woodlands, Texas, said positive data from the phase 1/ 2 trial with Tovaxin in multiple sclerosis indicate that after 12 months, patients exhibited a relapse rate reduction of more than 90%.

The company also said it has started animal studies at the University of Texas Medical Branch at Galveston using the company's autologous adult human stem cell regenerative medicine platform technology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.